Drotrecogin Alfa (Activated): A Pharmacoeconomic Review of its Use in Severe Sepsis

Author： Frampton J.E.   Foster R.H.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.22, Iss.7, 2004-01, pp. : 445-476

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

By McCoy Christopher  

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 625-637

Informa Healthcare

Access to resources Recommend Favorite

Drotrecogin-alfa relatively cost effective in severe sepsis

By  

Inpharma, Vol. 1, Iss. 1358, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Drotrecogin alfa improves organ function in severe sepsis

By  

Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Should patients with severe sepsis receive drotrecogin alfa?

By  

Inpharma, Vol. 1, Iss. 1508, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Drotrecogin-alfa warranted to tackle severe sepsis burden in Europe

By  

Inpharma, Vol. 1, Iss. 1368, 2002-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite